Rahul Mittal

As loss-of-exclusivity events accelerate, generics and biosimilars are diverging into distinct business models, demanding different regulatory, IP, and market access strategies from manufacturers.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

Rahul Mittal explains how execution infrastructure can help generics manufacturers improve hospital access, reduce delays, and strengthen coordination.

Rahul Mittal shows how execution infrastructure can improve access, cut delays, and strengthen coordination for generic drug manufacturers in hospitals.

To fix America's drug shortages, pharma must look beyond manufacturing and overhaul how medicines are allocated and delivered to smaller hospitals.

Chronic shortages expose how low prices, fragile supply chains, and misaligned incentives are undermining the U.S. generic drug market.